NCT06477107

A Study of Cerebral Perfusion With tDCS in Chronic Hypoperfusion

Completed
NAAges 18+InterventionalSupportive care
Mayo Clinic
~7 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:Soterix® 4x1HD-TDCSSoterix® 1x1 tDCSCognitive training program

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in cerebral blood flow
Measured over Phase 1 Day 0 and Phase 2 Day 0, 14, 44, and 58
Moyamoya Syndrome
Moyamoya Disease
Atheroscleroses, Cerebral
1 sites across 1 states
Minnesota1
  • Zafer Keser · PRINCIPAL_INVESTIGATOR · Mayo Clinic

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Vasculopathy leading to imaging evidence of hypoperfusion
Cognitive impairment

Exclusion

Pregnancy
Contraindication to MRI or tDCS including metallic implanted objects.
Medical instability or inability to cooperate during the study as assessed by the treating physician to participate in the study.
  • Changes in cerebral blood flowPhase 1 Day 0 and Phase 2 Day 0, 14, 44, and 58

    Cerebral blood flow imaging assessed by MRI to measure blood flow through the blood vessels reported in millimeters of mercury (mmHg)